Disease X ver1.0: COVID-19
Paul R Young
+ Author Affiliations
- Author Affiliations
School of Chemistry and Molecular Biosciences, The University of Queensland, Qld, Australia. Email: p.young@uq.edu.au
Microbiology Australia 41(2) 109-112 https://doi.org/10.1071/MA20028
Published: 27 May 2020
Journal Compilation © Australian Society for Microbiology 2020 Open Access CC BY
Abstract
The SARS-Cov2 has presented the world with a novel pandemic challenge requiring a rapid response. This article provides a May 2020 snapshot from Professor Paul Young, who is part of a group working with urgency on Australia’s leading COVID-19 candidate vaccine.
References
[1] Chappell, K. et al. (2018) Chimeric molecules and uses thereof. WO/2018/176103.[2] Magro, M. et al. (2012) Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc. Natl. Acad. Sci. USA 109, 3089–3094.
| Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention.Crossref | GoogleScholarGoogle Scholar | 22323598PubMed |
